In the near future, CureVac wants to take decisive steps in building production and transport capacities for its COVID-19 vaccine candidate, which is currently in development
CVnCoV go. “The preparations for the start of production and the necessary technology transfer are in progress,” reported the biotech company from Tübingen on Tuesday. In the coming weeks, CDMO and supplier partnerships will be announced in various European countries, according to the Süddeutsche Gesellschaft.
“It is our goal to increase production capacity within a short period of time in order to ensure a stable supply of our vaccine candidate,” says Florian von der Mülbe, Chief Production Officer of CureVac. “We are currently working with experienced partners across Europe to build a solid production network. Geographical proximity is an important factor to facilitate alignment and technology transfer, ”says the manager.
Yesterday the company announced an upcoming European Commission order to supply 225 million doses of CVnCoV and an option for an additional 180 million doses of the potential COVID-19 vaccine – we reported.
More about biotech stocks on 4investors: click here
At a glance – chart and news: CureVac